Advertisement
Advertisement
U.S. markets close in 4 hours 34 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Novozymes A/S (NZM2.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
57.04-0.84 (-1.45%)
As of 03:54PM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close57.88
Open57.40
Bid56.94 x 50000
Ask57.28 x 50000
Day's Range56.50 - 57.40
52 Week Range47.55 - 72.64
Volume0
Avg. Volume27
Market Cap17.135B
Beta (5Y Monthly)N/A
PE Ratio (TTM)39.45
EPS (TTM)1.45
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for NZM2.SG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      As one of the first companies in the world, Novozymes has had its net-zero target validated by the Science Based Targets initiative

      Novozymes has renewed its climate targets and by 2030 will reduce its absolute CO2 emissions across its operation by 75% and reduce its absolute CO2 emissions from its supply chain by 35%. By 2050, Novozymes will reach net-zero. COPENHAGEN, Denmark – November 10, 2022. Novozymes’ first science-based targets were approved in 2019. Today Novozymes has new, SBTi approved near and long-term science-based emission reduction targets and is one of the first companies in the world to have committed to S

    • GlobeNewswire

      Novozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth

      COPENHAGEN, Denmark – November 10, 2022. Novozymes, the world leader in biological solutions, and LinusBio (Linus Biotechnology Inc.), a leader in precision exposome sequencing, today announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial. The project will apply LinusBio’s environmental biodynamics platform, enabling detailed temporal mapping of harmful compound exposure, to a clinical trial of probiotics sponsored by Novozymes’ human healt

    • GlobeNewswire

      Novozymes confirms upgraded guidance by strong start to Q4

      Novozymes delivered 9% organic sales growth in the first nine months of 2022 and 6% organic sales growth in the third quarter. As announced on October 7, the full-year organic sales growth outlook was raised from 6-8 % to now 8-9 % following a strong performance in the first nine months of the year, and expectedly, continued strong Q4 momentum. COPENHAGEN, Denmark – November 3, 2022. In the first nine months of the 2022 financial year, Novozymes delivers 9% organic sales growth, an EBIT-margin o

    Advertisement
    Advertisement